Tonix Pharma | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 1.998 M

LB filings
2025.08.11 20:48
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 1.998 M, missing the estimate of USD 2.433 M.

EPS: As of FY2025 Q2, the actual value is USD -3.86, missing the estimate of USD -2.92.

EBIT: As of FY2025 Q2, the actual value is USD -28.3 M.

Segment Revenue

  • Product Revenue, Net: For the three months ended June 30, 2025, product revenue was $1.998 million, compared to $2.208 million for the same period in 2024. For the six months ended June 30, 2025, product revenue was $4.427 million, compared to $4.690 million in 2024.

Operational Metrics

  • Operating Loss: For the three months ended June 30, 2025, the operating loss was - $28.296 million, compared to - $77.316 million for the same period in 2024. For the six months ended June 30, 2025, the operating loss was - $44.350 million, compared to - $98.667 million in 2024.
  • Net Loss: For the three months ended June 30, 2025, the net loss was - $28.272 million, compared to - $78.776 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was - $45.101 million, compared to - $93.715 million in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was - $31.412 million, compared to - $27.494 million in 2024.
  • Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $60.526 million, compared to $6.813 million in 2024.

Unique Metrics

  • Grant Income: For the three months ended June 30, 2025, grant income was $1.036 million, compared to $0 in 2024. For the six months ended June 30, 2025, grant income was $1.959 million, compared to $0 in 2024.

Future Outlook and Strategy

  • Core Business Focus: Tonix Pharmaceuticals Holding Corp. is prioritizing the advancement of TNX-102 SL for the management of fibromyalgia, with a PDUFA goal date of August 15, 2025, for marketing authorization. The company is also developing TNX-102 SL for acute stress reaction and acute stress disorder, with topline results expected in the second half of 2026.
  • Non-Core Business: The company is developing TNX-1500 for the prevention of allograft rejection and autoimmune diseases, and TNX-1700 for gastric and colorectal cancers. Additionally, TNX-801 and TNX-4200 are being developed for infectious diseases, with a contract from the DoD for up to $34 million over five years to develop TNX-4200.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.